Who is sponsoring NCT00448240?

NCT00448240 is sponsored by Henry Ford Health System.

What condition does NCT00448240 study?

NCT00448240 studies Head and Neck Cancer, Carcinoma, Squamous Cell.

What is the status of NCT00448240?

NCT00448240 is currently TERMINATED.

Last reviewed 2025-02-26 · How we verify

Erlotinib (Tarceva) Given Intermittently During First Line Standard Platinum Containing Chemotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00448240 Phase 2/Phase 3 TERMINATED Results posted

The purpose of this study is to determine if combination Erlotinib, Cisplatin/Carboplatin, and Paclitaxel are effective first line treatment for metastatic, recurrent and persistent squamous cell carcinoma of the head and neck.

Details

Lead sponsor	Henry Ford Health System
Phase	Phase 2/Phase 3
Status	TERMINATED
Enrolment	6
Start date	2007-02
Completion	2012-01

Conditions

Head and Neck Cancer
Carcinoma, Squamous Cell

Interventions

Erlotinib

Primary outcomes

Tumor Response Rate of Intermittent Tarceva During First Line Standard Platinum Containing Chemotherapy — Evaluated at 6-week intervals, up to an average of 18 weeks.
Response rate of intermittent Tarceva will be measured by applying RECIST 1.0 criteria to measure response using radiologic testing.